No, Kenalog (triamcinolone acetonide) is not recommended as a standard treatment for postherpetic neuralgia
Kenalog is not FDA-approved for postherpetic neuralgia, and current clinical practice guidelines do not include systemic or intra-articular corticosteroids as recommended therapies for this condition. 1
Why Kenalog Is Not Appropriate
The FDA-approved indications for Kenalog include allergic states, dermatologic diseases, endocrine disorders, and rheumatic disorders—but postherpetic neuralgia is notably absent from this list 1. The drug label specifically warns against certain routes of administration and emphasizes its use for inflammatory conditions, not neuropathic pain syndromes 1.
Evidence-Based First-Line Treatments for Postherpetic Neuralgia
Multiple high-quality guidelines consistently recommend the following approach:
Start with gabapentin or pregabalin
- Gabapentin is the first-line oral pharmacological treatment (strong recommendation, moderate evidence) 2, 3
- Pregabalin is FDA-approved specifically for postherpetic neuralgia and shows efficacy with NNT of 4.93 3
- Typical gabapentin dosing: start 100-300 mg nightly, titrate to 900-3600 mg daily in divided doses 4, 5
Alternative first-line options:
- Tricyclic antidepressants (nortriptyline or desipramine preferred over amitriptyline due to better tolerability): NNT 2.64 for postherpetic neuralgia 3, 6
- Duloxetine (SNRI): FDA-approved for diabetic neuropathy, effective for neuropathic pain 2
- Topical lidocaine 5% patches: NNT of 2, minimal systemic absorption 4, 3, 7
- High-concentration capsaicin 8% patch: Strong recommendation for topical treatment, single 30-minute application provides relief for up to 12 weeks 3
The Limited Role of Corticosteroids
Subcutaneous injection only—not systemic or intra-articular:
While some older research suggests subcutaneous injection of triamcinolone with lidocaine directly into affected dermatomes during acute herpes zoster may prevent progression to postherpetic neuralgia 8, 9, 10, 11, this is distinctly different from:
- Intramuscular Kenalog injection (which you're asking about)
- Intra-articular injection (indicated only for joint conditions) 1
- Oral corticosteroids for established postherpetic neuralgia
Critical distinction: A 2023 Cochrane review found very low-certainty evidence that oral corticosteroids during acute herpes zoster prevent postherpetic neuralgia (RR 0.95% CI 0.45-1.99), with no demonstrated benefit once postherpetic neuralgia is established 12.
Intrathecal corticosteroids carry serious risks:
One systematic review noted intrathecal lidocaine with methylprednisolone showed analgesic efficacy (NNT 1.13), but this approach has been associated with reports of arachnoiditis and should be undertaken with extreme caution 3, 13, 8.
Recommended Treatment Algorithm
- Initiate gabapentin or pregabalin as first-line therapy
- Add topical lidocaine patches for localized pain (can be used concurrently)
- If inadequate response to gabapentin: switch to or add tricyclic antidepressant (nortriptyline) or duloxetine 3
- Consider high-concentration capsaicin patch if other topicals insufficient 3
- Reserve opioids only for refractory cases or acute severe exacerbations, not as first-line 2, 3
Common Pitfalls to Avoid
- Do not use Kenalog IM or intra-articular for postherpetic neuralgia—it lacks evidence and FDA approval for this indication
- Do not confuse prevention strategies (subcutaneous triamcinolone during acute zoster) with treatment of established postherpetic neuralgia
- Avoid epidural or intrathecal corticosteroids due to serious adverse event risks including arachnoiditis 1, 8
- Do not prescribe opioids as first-line therapy for chronic neuropathic pain 3
In older adults, start all medications at lower doses and titrate slowly due to increased risk of adverse effects, particularly with tricyclic antidepressants (anticholinergic effects) and gabapentinoids (somnolence, dizziness, falls) 5, 6.